2021 prediction: these 10 drugs sell best (list attached)

Attention medical representatives, These 10 drugs have the highest sales potential

1.

(Image source: Yao Chunqiu)

Among them, Merck’s pembrolizumab, Gilead’s Bicampinox tablets, Eli Lilly’s dulaglutide, AstraZeneca’s osimertinib and Novartis’s secukinumab are among the top five, 2020 Annual sales increased by 30%, 67%, 23%, 38% and 21% year-on-year.

PD-1 and PD-L1 drugs, including K drug, secukinumab, darelimumab, duplizumab, atilizumab, and imelizumab, are on the list Occupying six seats is enough to prove the future development prospects of this class of drugs.

2.

In the PD-1 battle, K medicine won a key victory in the battle for the first-line lung cancer treatment with O medicine, and achieved a counterattack: In 2016, the sales of O medicine were nearly three times that of K medicine; in 2020, K medicine sales The amount is close to 15 billion US dollars, which is nearly twice the sales of O medicine.

Merck’s 2020 annual report shows that K medicine has reached the second position in the world with a sales of 14.

To some extent, the dispute between O drugs and K drugs is a dispute over indications, and it is also a situation that all PD-1 drugs must face: In 2016, O drugs have been used in melanoma, head and neck cancer, lung cancer, kidney cancer, etc.

However, in the Phase III study of the first-line treatment of non-small cell lung cancer, the most common type of lung cancer, drug O failed to reach the clinical endpoint, and drug K opened the way to counterattack.

Today, drug K has been approved for the treatment of 19 indications such as classic Hodgkin’s lymphoma, skin squamous cell carcinoma, esophageal cancer, gastric or gastroesophageal junction adenocarcinoma, and it is still two consecutive times in the context of high epidemics.

3.

This variety is also of profound significance to AZ.

According to data, osimertinib was approved in the United States in November 2015 and approved in China in March 2017, making it the fastest imported anti-cancer drug ever to enter the country.

In order to promote the sales of Teresa, AstraZeneca’s gefitinib won the bid with a 76% drop in the 4+7 volume procurement pilot.

4.
In the hypoglycemic field, GLP-1 has a gratifying increase

According to Yao Chunqiu data, two hypoglycemic drugs from Eli Lilly’s dulaglutide and Novo Nordisk’s semaglutide entered the list this time, and both are GLP-1 drugs.
The sales data of dulaglutide in 2020 is 5.
07 billion U.
S.
dollars.
Semaglutide, the "successor" of GLP-1, also won the most sales potential drug with a high growth of 119% and dazzling data of 3.
69 billion U.
S.
dollars.
Ranked eighth.

GLP-1 is a kind of "incretin" naturally secreted by the mucosa of the human gastrointestinal tract.
GLP-1 receptor agonist type hypoglycemic drugs are currently one of the best-selling hypoglycemic drugs.
The incidence is significantly lower than insulin, and it can reduce food intake and delay gastric emptying, which is conducive to weight control and can protect pancreatic β-cell function.

Eli Lilly’s dulaglycotide injection was approved by the National Food and Drug Administration to enter the Chinese market in February 2019.
The product was approved by the FDA in 2014 and its sales have been rising since it was launched.
In 2017, it exceeded the US$2 billion mark for the first time.
A year-on-year increase of 119.
46%.